In conclusion, our findings provide evidence that bevacizumab, an FDA-approved drug, plays a protective role in disc degeneration by inhibiting VEGF expression and promoting extracellular matrix synthesis. This evidence concerns the gene VEGFA and intervertebral disk degenerative disorder.